TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T74500	Voltage-gated potassium channel Kv4.3	D00PEH	Eltrombopag	Approved	135449332	C25H22N4O4	442.5	.	IC50 = 1584893.19 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D09MWJ	Alfuzosin	Approved	2092	C19H27N5O4	389.4	CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC	IC50 = 1000000 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D0BP9C	Etravirine	Approved	193962	C20H15BrN6O	435.3	CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N	IC50 = 3162277.66 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D0E6XR	Dasatinib	Approved	3062316	C22H26ClN7O2S	488	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO	IC50 = 316227.77 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D0I1FQ	Raltegravir	Approved	54671008	C20H21FN6O5	444.4	.	IC50 = 5011872.34 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D0K3QS	Everolimus	Approved	6442177	C53H83NO14	958.2	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC	IC50 = 10000000 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D0L3MP	VRX496	Approved	64143	C32H45N3O4S	567.8	CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O	IC50 = 5011872.34 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D0O3FG	Desvenlafaxine	Approved	125017	C16H25NO2	263.37	CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O	IC50 = 5011872.34 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D0U0VU	SILODOSIN	Approved	5312125	C25H32F3N3O4	495.5	C[C@H](CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F	IC50 = 316227.77 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D0U2JP	Sitagliptin	Approved	4369359	C16H15F6N5O	407.31	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N	IC50 = 100000000 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D0X5ZI	Ambrisentan	Approved	6918493	C22H22N2O4	378.4	CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C	IC50 = 251188.64 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D0Z7ZM	Rhucin	Approved	135398744	C22H30N6O4S	474.6	CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C	IC50 = 501187.23 nM	Non binder
T74500	Voltage-gated potassium channel Kv4.3	D06GGT	MCL-1-specific antisense oligonucleotide + nilotinib (AMN107)	Investigative	644241	C28H22F3N7O	529.5	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	IC50 = 3162277.66 nM	Non binder